Drug companies AstraZeneca and Pfizer are being attacked by the EU over vaccine delivery delays that could slow the EU’s recovery from Covid-19, says Julia Horowitz on CNN. Pfizer’s problems look likely to be resolved soon, however, while AstraZeneca says “considerably fewer” doses will be supplied for some time. With AstraZeneca’s jab due to be approved by Europe’s regulator shortly, “mounting” anger means that Brussels and several countries are “threatening to take legal action and introduce export controls on doses produced in the bloc” (see page 8).
AstaZeneca’s announcement will prolong the “misery and pain” of Covid-19, says Aimee Donnellan on Breakingviews. Still, problems were “inevitable” as the vaccine, developed by the University of Oxford, is made “through a complicated biological process, requiring constant fine-tuning and vast 4,000-litre fermenters, which are in short supply”.
AstraZeneca’s problems are good news for the jab produced by Janssen, Johnson & Johnson’s European vaccine division, which the EU has pre-ordered in large amounts, says the Irish Times. Like the AstraZeneca jab, it doesn’t require “ultra-cold storage temperatures”; but unlike all its major competitors, it also involves a single injection, “greatly simplifying... a national vaccine rollout”. With trial data expected in the next few days, the vaccine is set to receive approval from the US Food and Drug Administration sometime in February, with the nod from the European Medicines Agency expected not long afterwards.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
8 of the best properties for sale with indoor swimming poolsThe best properties for sale with indoor swimming pools – from an award-winning contemporary house in East Sussex, to a converted barn in Hampshire
-
Chinese stocks slump on first trading day of 2025Chinese stocks suffered in the new year from their worst first day of trading since 2016, despite a state stimulus package
-
Why Wise could be worth a lot more than its share price impliesForeign-exchange transfer service Wise has the potential to become the Amazon of its sector – here's why you should consider buying this stock now
-
Can The Gym Group pump up your portfolio?Gym Group was one of the best UK small-cap stocks in 2024 and will beef up your profits this New Year
-
MoneyWeek's five predictions for investors in 2025MoneyWeek's City columnist gazes into his crystal ball and sees five unexpected events in store for investors in 2025
-
How buy-and-build stocks deliver strong returnsBunzl, DCC and Diploma became successful through buy-and-build – rolling up dozens of unglamorous businesses. How does it work and what makes it successful?
-
Singapore Technologies Engineering shows strong growthSingapore Technologies Engineering offers diversification, improving profitability and income
-
Royal Mail takeover by Czech billionaire approved for £3.6bnRoyal Mail is now owned by Czech billionaire Daniel Kretinsky, following a £3.6 billion takeover
-
AstraZeneca goes cheap – should you buy?The decline in AstraZeneca’s share price is overdone given the outlook, and the stock is cheap
-
Why undersea cables are under threat – and how to protect themUndersea cables power the internet and are vital to modern economies. They are now vulnerable
